KDM1A and Alzheimer disease: In addition, TAK-418 and TAK-448 (Figure 5A) are highly enzyme-specific LSD1 inhibitors without impact on LSD1 complex, and both compounds are reported to show therapeutic potentials for cancer, AD, autism symptom disorder and Kabuki syndrome et al. (Baba et al., 2021; Yin et al., 2021; Baba et al., 2022).